OncoImmune closes $15mm Series A round
Immunotherapies firm OncoImmune Inc. raised $15mm through its Series A round from lead investor 3E Bioventures Capital and other undisclosed buyers.
- Large Molecule
- Venture Financing
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.